|
Re: Potential Market Size
|
1
|
Resverlogix Corp.
|
Apr 18, 2019 12:27PM
|
|
Re: noticed Hepalink hasn't followed the same pattern over the last month..
|
|
Resverlogix Corp.
|
May 09, 2019 10:07AM
|
|
Re: NLRP3 inhibitors and apabetalone
|
6
|
Resverlogix Corp.
|
Jul 26, 2019 01:24PM
|
|
Re: NLRP3 inhibitors and apabetalone
|
5
|
Resverlogix Corp.
|
Jul 26, 2019 01:32PM
|
|
Re: News
|
5
|
Resverlogix Corp.
|
Aug 12, 2019 06:12PM
|
|
Re: New article on BET Inhibitors in Cardiovascular Disease
|
6
|
Resverlogix Corp.
|
Jan 30, 2019 01:30PM
|
|
Re: NASH is a $35 Billion US/year market
|
1
|
Resverlogix Corp.
|
Dec 31, 2018 07:21PM
|
|
Re: NASH is a $35 Billion US/year market
|
2
|
Resverlogix Corp.
|
Dec 31, 2018 09:38PM
|
|
Re: MOA of Apabetalone - only affects sick patients
|
2
|
Resverlogix Corp.
|
Apr 15, 2019 08:46AM
|
|
Re: MOA of Apabetalone - only affects sick patients
|
5
|
Resverlogix Corp.
|
Apr 15, 2019 09:42AM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 03, 2018 01:02PM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 04, 2018 06:16AM
|
|
Re: MACE event rate
|
4
|
Resverlogix Corp.
|
Nov 04, 2018 08:24AM
|
|
Re: MACE event rate
|
4
|
Resverlogix Corp.
|
Nov 04, 2018 10:58AM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 04, 2018 11:16AM
|
|
Re: Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL
|
6
|
Zenith Epigenetics
|
Nov 22, 2018 01:42PM
|
|
Re: Last hour.....
|
1
|
Resverlogix Corp.
|
May 31, 2019 03:48PM
|
|
Re: Last hour.....
|
4
|
Resverlogix Corp.
|
Jun 01, 2019 01:51AM
|
|
Re: Kudos to Dr. Kausik Ray
|
1
|
Resverlogix Corp.
|
Mar 13, 2019 07:36PM
|
|
Re: J&J Abiraterone going generic
|
2
|
Zenith Epigenetics
|
Nov 21, 2018 03:48PM
|
